^
BIOMARKER:

EGFR L861Q

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR L861Q
NSCLC
afatinib
Sensitive: B - Late Trials
EGFR L861Q
NSCLC
gefitinib
Sensitive: B - Late Trials
EGFR L861Q
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR L861Q
LUAD
osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR L861Q
NSCLC
erlotinib
Sensitive: C2 – Inclusion Criteria
EGFR L861Q
NSCLC
osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR L861Q
NSCLC
dacomitinib
Sensitive: C2 – Inclusion Criteria
EGFR L861Q
LUAD
afatinib
Sensitive: C3 – Early Trials
EGFR L861Q
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR L861Q
Lung Cancer
pan-ErbB inhibitor
Sensitive: D – Preclinical
EGFR L861Q
Esophageal Cancer
erlotinib
Resistant: D – Preclinical
EGFR L861Q
Esophageal Cancer
cetuximab
Resistant: D – Preclinical
EGFR L861Q
Esophageal Cancer
afatinib
Sensitive: D – Preclinical